{"name":"Zalicus","slug":"zalicus","ticker":"","exchange":"","domain":"","description":"Zalicus is a biopharmaceutical company focused on the discovery and development of innovative therapies to address significant unmet medical needs. The company has a diverse pipeline of drug candidates in various stages of clinical development, with a strong emphasis on neurology and pain management.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":14731000,"revenueGrowth":291.2,"grossMargin":0,"rdSpend":30925000,"netIncome":-138759000,"cash":72264000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CRx-197","genericName":"CRx-197","slug":"crx-197","indication":"Chronic pain","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"nortriptyline HCl","genericName":"nortriptyline HCl","slug":"nortriptyline-hcl","indication":"Depression","status":"marketed"}]}],"pipeline":[{"name":"CRx-197","genericName":"CRx-197","slug":"crx-197","phase":"phase_2","mechanism":"CRx-197 is a small molecule that modulates the TRPV1 receptor.","indications":["Chronic pain"],"catalyst":""},{"name":"nortriptyline HCl","genericName":"nortriptyline HCl","slug":"nortriptyline-hcl","phase":"marketed","mechanism":"Small molecule","indications":["Depression","Endogenous Depression"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPUVFxbl9mN2pzakJsbl9FUV9ZaTBwYmp1UXNISVo4TmEwMXBQWWNnQUtIZ2tfNGdGLTJVTXFNeHVWd3FHdUxxdzI2c1o5RHk4a1dDUzBEbzR1Tzg1ckphaldsMEs5SWkwOXVjbi1JNHFCb1RTcE5CNWVObVNhWUR5czR5Q3FyTjVLU2pJbGdwaHZ1aHlPbkJNWkFPdkhkeDhwNm9fVmZueGRvc0RoRmNxQ1loUllkTWNYRHhjVFhOWGFmUXhGSXpqZzNnd0p6c3M?oc=5","date":"2026-03-10","type":"pipeline","source":"The Globe and Mail","summary":"Zevra Therapeutics Appoints Justin Renz as New CFO - The Globe and Mail","headline":"Zevra Therapeutics Appoints Justin Renz as New CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOc1BBbWVDZTlnc2JVNm9Xb2hJM0tpMmJ4NGpOVHlfNmRyOEgtUDhlYW4wc2xma1BvdVA0RFQwMDZqVUxCQnVsVUVrOEdfV3FqbnBONGt4S0dxWTFCcUpJOEo4QUpDMTJjR19KN0xwZnVGbXVVRXQwREFiU0F2WTJmSmw4N3JhN1ZmZEhVTmxKN2c3NUk5dmNjYzhvTGRpWFA5?oc=5","date":"2021-08-14","type":"deal","source":"Generics and Biosimilars Initiative","summary":"Biosimilar merger for Epirus and collaboration for Catalent - Generics and Biosimilars Initiative","headline":"Biosimilar merger for Epirus and collaboration for Catalent","sentiment":"neutral"},{"date":"2016-08-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2016-07-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2016-07-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2016-06-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2016-05-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2016-05-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2016-03-29","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPNUxVTUhwQ3JvcDdtZE1WNmsyNUFEQmxGMm01QTZfZkZaQ3NET3lET3BRZExKeW9SUEFOOVE3YW5mZUN2RG03Q3lQNEFvc0hyUnpMdjc3N2hqelg5QUF5OUs5VUpyT1lzWHdOQjFyZzdodFN0VzY5WHlBYW81dThrWkVYSlZQcEpkbUQ0VzloRDg1QlYxbkY0cWx3cVdIWG80X0lOOFR5UkJaalBIRjFwWllEbGczR2d0OGNMR3dFdVJtU2otS0lj?oc=5","date":"2014-08-08","type":"pipeline","source":"Karyopharm","summary":"Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer - Karyopharm","headline":"Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":14731000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":14731000,"period":"2013-12-31"},{"value":3766000,"period":"2013-12-31"},{"value":3400000,"period":"2013-09-30"},{"value":3891000,"period":"2013-06-30"},{"value":3674000,"period":"2013-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":30925000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-138759000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":72264000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}